Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - DoubtfulReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exponent (EXPO) Other Accumulated Expenses (2018 - 2026)

Exponent's Other Accumulated Expenses history spans 7 years, with the latest figure at $2.1 million for Q1 2026.

  • For the quarter ending Q1 2026, Other Accumulated Expenses fell 3.91% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Jan 2026, down 3.91%, and an annual FY2026 reading of $2.1 million, down 3.91% over the prior year.
  • Other Accumulated Expenses for Q1 2026 was $2.1 million at Exponent, down from $2.2 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $5.6 million in Q4 2023, with the low at $2.1 million in Q1 2026.
  • Average Other Accumulated Expenses over 4 years is $3.7 million, with a median of $3.6 million recorded in 2022.
  • Year-over-year, Other Accumulated Expenses grew 12.87% in 2023 and then crashed 60.0% in 2025.
  • Tracing EXPO's Other Accumulated Expenses over 4 years: stood at $4.9 million in 2022, then increased by 12.87% to $5.6 million in 2023, then crashed by 60.0% to $2.2 million in 2025, then decreased by 3.91% to $2.1 million in 2026.
  • Per Business Quant, the three most recent readings for EXPO's Other Accumulated Expenses are $2.1 million (Q1 2026), $2.2 million (Q1 2025), and $5.6 million (Q4 2023).